Skip to main content

Table 2 Predictors of death during treatment (n = 565).

From: Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis

Predictors   Death during treatment
N (%)
Unadjusted
HR (95% CI), p value
Adjusted
HR (95% CI), p value
N   37   
Mean age at diagnosis ± SD (hazard/10 year increase)   45 ± 16 1.26 (1.03-1.55), 0.03 1.52 (1.18-1.95), 0.001
Gender Male 29 (6.4) 0.98 (0.44-2.14), 0.95  
  Female 8 (7.1)   
Ethnicity Hispanic 7 (4.2) 0.55 (0.24-1.27), 0.16  
  Non-Hispanic 30 (7.5)   
Place of birth U.S. 31 (7.9) 2.92 (1.10-7.74), 0.03 2.70 (0.96-7.63), 0.06
  Foreign 6 (3.5)   
HIV status Positive 24 (11.8) 2.30 (1.14-4.61), 0.02 2.57 (1.17-5.64), 0.02
  Negative/Unknown 13 (3.6)   
DOT1 Yes/Partial* 32/373 (8.6) 2.65 (1.02-6.87), 0.04 1.31 (0.47-3.64), 0.61
  No 5/190 (2.6)   
Episode of inadequate therapy during intensive phase2 Yes 24/153 (15.7) 3.39 (1.68-6.83), 0.001 3.15 (1.52-6.52), 0.002
  No 13/409 (3.2)   
Episode of inadequate therapy during continuation phase3 Yes 10/126 (7.9) 0.72 (0.32-1.65), 0.44  
  No 23/430 (5.4)   
Sputum smear status Positive 27 (10.4) 2.97 (1.43-6.17), 0.004 3.07 (1.44-6.56), 0.004
  Negative 10 (3.3)   
Extrapulmonary in addition to pulmonary Yes 18 (11.2) 1.69 (0.85-3.34), 0.13  
  No 19 (4.7)   
Cavitary disease Yes 4 (3.0) 0.43 (0.15-1.23), 0.12  
  No 33 (7.6)   
Any prior medical condition Yes 25 (8.0) 1.74 (0.85-3.54), 0.13  
  No 12 (4.8)   
  1. 1) Excluding 2 with missing data for directly observed therapy. * Partial DOT = DOT used for less than the full duration of treatment (clinicians opted to transition select patients to self-administered therapy (SAT) at the end of the intensive phase of treatment, or initiated DOT in patients previously treated by SAT in whom clinical, radiographic or microbiologic response to treatment was delayed). 2) Excluding 3 with missing data for intensive phase. 3) Excluding 9 with missing data for continuation phase. Note-HR = hazard ratio